A ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells
Authors:
- Amineh GhaderiAGAmineh Ghaderi
- Wen ZhongWZWen Zhong
- Mohammad Ali OkhovatMOMohammad Ali Okhovat
- Johanna AschanJAJohanna Aschan
- Ann SvenssonASAnn Svensson
- Birgitta SanderBSBirgitta Sander
- Johan SchultzJSJohan Schultz
- Thomas OlinTOThomas Olin
- Anders ÖsterborgAÖAnders Österborg
- Mohammad Hojjat-FarsangiMohammad Hojjat-Farsangi
- Håkan MellstedtHMHåkan Mellstedt
Open Access
- 20 October 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (10) , 2238
Abstract
The receptor tyrosine kinase orphan receptor 1 (ROR1) is absent in most normal adult tissues but overexpressed in various malignancies and is of importance for tumor cell survival, proliferation, and metastasis. In this study, we evaluated the apoptotic effects of a novel small molecule inhibitor of ROR1 (KAN0441571C) as well as venetoclax (BCL-2 inhibitor), bendamustine, idelalisib (PI3Kδ inhibitor), everolimus (mTOR inhibitor), and ibrutinib (BTK inhibitor) alone or in combination in human MCL primary cells and cell lines. ROR1 expression was evaluated by flow cytometry and Western blot (WB). Cytotoxicity was analyzed by MTT and apoptosis by Annexin V/PI staining as well as signaling and apoptotic proteins (WB). ROR1 was expressed both in patient-derived MCL cells and human MCL cell lines. KAN0441571C alone induced significant time- and dose-dependent apoptosis of MCL cells. Apoptosis was accompanied by decreased expression of MCL-1 and BCL-2 and cleavage of PARP and caspase 3. ROR1 was dephosphorylated as well as ROR1-associated signaling pathway molecules, including the non-canonical WNT signaling pathway (PI3Kδ/AKT/mTOR). The combination of KAN0441571C and ibrutinib, venetoclax, idelalisib, everolimus, or bendamustine had a synergistic apoptotic effect and significantly prevented phosphorylation of ROR1-associated signaling molecules as compared to KAN0441571C alone. Our results suggest that targeting ROR1 by a small molecule inhibitor, KAN0441571C, should be further evaluated particularly in combination with other targeting drugs as a new therapeutic approach for MCL.Keywords
Funding Information
- the Åke Olsson Foundation for Hematology Research (2017-00436, 2019-00396)
- Insamlingsstiftelsen Cancer- och Allergifonden (2016/5, 2017/63, 2018/63, 2019/189, 2020/258, 2017/64, 2018/140, 2019/194, 2020/260)
- the Cancer Society in Stockholm (CAN 2015/408, CAN 2018/499)
- AFA Försäkring (130054)
- The Karolinska Institutet Foundation
- Region Stockholm (20150070, 20180030)
This publication has 45 references indexed in Scilit:
- ROR1 Is Expressed in Human Breast Cancer and Associated with Enhanced Tumor-Cell GrowthPLOS ONE, 2012
- Wnt5a–Ror–Dishevelled signaling constitutes a core developmental pathway that controls tissue morphogenesisProceedings of the National Academy of Sciences, 2012
- Responses in Mantle Cell Lymphoma Cells to SNS-032 Depend on the Biological Context of Each Cell LineCancer Research, 2010
- Ror‐family receptor tyrosine kinases in noncanonical Wnt signaling: Their implications in developmental morphogenesis and human diseasesDevelopmental Dynamics, 2009
- Bcl2 family proteins in carcinogenesis and the treatment of cancerApoptosis, 2009
- Ror receptor tyrosine kinases: orphans no moreTrends in Cell Biology, 2008
- Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- Activation of Mammalian Target of Rapamycin Signaling Promotes Cell Cycle Progression and Protects Cells from Apoptosis in Mantle Cell LymphomaThe American Journal of Pathology, 2006
- Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphomaBlood, 2006
- Expression and Function of the Ror‐Family Receptor Tyrosine Kinases During Development: Lessons from Genetic Analyses of Nematodes, Mice, and HumansJournal of Receptors and Signal Transduction, 2003